Literature DB >> 5529238

The recombination of dimers of immunoglobulin peptide chains.

G T Stevenson, K J Dorrington.   

Abstract

1. Both the gamma and light peptide chains of human pooled and myeloma immunoglobulin G can be prepared as non-aggregating dimers at pH5.4 in 4mm-sodium acetate buffer. The dimeric state is maintained by non-covalent bonds, since the formation of interchain disulphide bonds was prevented by alkylation of the thiol groups. In the case of the light chains there is some evidence that the dimers are in equilibrium with a small amount of monomer. 2. When such dimers of the gamma and light chains are mixed at pH5.4 in 4mm-sodium acetate buffer they combine rapidly, yielding a product that resembles the original immunoglobulin G in its physicochemical and antigenic properties. However, the original optical rotatory dispersion spectrum was regained only with the homogeneous myeloma protein. The recombined pooled immunoglobulin G had a spectrum slightly different from the original, suggesting that at least some of the recombinant molecules had not regained native conformations. 3. Dimers of gamma chains stabilized by interchain disulphide bonds were able to recombine with light chains. However, light chains stabilized in the dimeric state by interchain disulphide bonds would not combine with gamma chains. 4. The chains of rabbit immunoglobulin G behave similarly to the human chains in this system, apart from the alkylated light chains showing clearer evidence of monomeric components.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5529238      PMCID: PMC1179278          DOI: 10.1042/bj1180703

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  20 in total

1.  Conformational change and complementarity in the combination of H and L chains of immunoglobulin-G.

Authors:  K J Dorrington; M H Zarlengo; C Tanford
Journal:  Proc Natl Acad Sci U S A       Date:  1967-09       Impact factor: 11.205

2.  Studies on the conformation of purified human and canine gamma-A-globulins and equine gamma-T-globulin by optical rotatory dispersion.

Authors:  K J Dorrington; J H Rockey
Journal:  J Biol Chem       Date:  1968-12-25       Impact factor: 5.157

3.  Equine antihapten antibody. VI. Subunits of polyalanylated gamma-G(T)-immunoglobulin.

Authors:  R J Genco; F Karush; H S Tenenhouse
Journal:  Biochemistry       Date:  1968-07       Impact factor: 3.162

4.  Specific dimerization of the light chains of human immunoglobulin.

Authors:  G T Stevenson; D Straus
Journal:  Biochem J       Date:  1968-07       Impact factor: 3.857

5.  Relationships of two light chain immunoglobulins isolated from the same human source (low molecular weight immunoglobins).

Authors:  H F Deutsch
Journal:  Immunochemistry       Date:  1965-09

6.  The optical rotatory dispersion of human gamma-M-immunoglobulins and their subunits.

Authors:  K J Dorrington; C Tanford
Journal:  J Biol Chem       Date:  1968-09-25       Impact factor: 5.157

7.  Recombination of the peptide chains of immunoglobulin G.

Authors:  G T Stevenson
Journal:  Bibl Haematol       Date:  1968

8.  Preparation and characterization of poly-DL-alanyl rabbit gamma-globulin.

Authors:  S Fuchs; M Sela
Journal:  J Biol Chem       Date:  1965-09       Impact factor: 5.157

9.  Optical rotatory dispersion studies of rabbit gamma-G-immunoglobulin and its papain fragments.

Authors:  L A Steiner; S Lowey
Journal:  J Biol Chem       Date:  1966-01-10       Impact factor: 5.157

10.  Biosynthesis of immunoglobulins. Free light chain as an intermediate in the assembly of gamma G-molecules.

Authors:  B A Askonas; A R Williamson
Journal:  Nature       Date:  1966-07-23       Impact factor: 49.962

View more
  19 in total

1.  A kinetic study in vitro of the reoxidation of interchain disulfide bonds in a human immunoglobulin IgGLk. Correlation between sulfhydryl disappearance and intermediates in covalent assembly of H2L2.

Authors:  D W Sears; J Mohrer; S Beychok
Journal:  Proc Natl Acad Sci U S A       Date:  1975-01       Impact factor: 11.205

2.  Recovery of immunoglobulin removed from lymphocytic surfaces by proteolysis.

Authors:  R P Eady; D W Hough; P J Kilshaw; G T Stevenson
Journal:  Immunology       Date:  1974-03       Impact factor: 7.397

3.  Some effects on leukaemic B lymphocytes of antibodies to defined regions of their surface immunoglobulin.

Authors:  F K Stevenson; E V Elliott; G T Stevenson
Journal:  Immunology       Date:  1977-04       Impact factor: 7.397

4.  An active derivative of rabbit antibody light chain composed of the constant and the variable domains held together only by a native disulfide bond.

Authors:  K Poulsen; K J Fraser; E Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1972-09       Impact factor: 11.205

5.  Thiol groups of normal human immunoglobulin G.

Authors:  B M Buchwald; G E Connell
Journal:  Biochem J       Date:  1974-02       Impact factor: 3.857

6.  The binding of haptens by the polypeptide chains of rabbit antibody molecules.

Authors:  G T Stevenson
Journal:  Biochem J       Date:  1973-08       Impact factor: 3.857

7.  Independent folding of the variable and constant halves of a lambda immunoglobulin light chain.

Authors:  I Björk; F A Karlsson; I Berggård
Journal:  Proc Natl Acad Sci U S A       Date:  1971-08       Impact factor: 11.205

8.  Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors.

Authors:  Andrea Franco; Bazarragchaa Damdinsuren; Tomoko Ise; Jessica Dement-Brown; Huifang Li; Satoshi Nagata; Mate Tolnay
Journal:  J Immunol       Date:  2013-04-24       Impact factor: 5.422

9.  Comparative studies on oestrogen-induced rat uterus peroxidase and rat eosinophil peroxidase.

Authors:  R L Olsen; C Little
Journal:  Biochem J       Date:  1982-12-01       Impact factor: 3.857

10.  Rat eosinophil-mediated antibody-dependent cellular cytotoxicity: investigations of the mechanisms of target cell lysis and inhibition by glucocorticoids.

Authors:  C Hallam; D I Pritchard; S Trigg; R P Eady
Journal:  Clin Exp Immunol       Date:  1982-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.